Abstract:Cisplatin is widely used in the chemoradiotherapy (CRT) of cervical cancers. However, despite the severe systemic side effects, the therapeutic efficacy of cisplatin is often compromised by the development of drug resistance, which is closely related to the elevated intracellular thiol-containing species (especially glutathione (GSH)) and the adenosine triphosphate (ATP)-dependent glutathione S-conjugate pumps. The construction of a safe and redox-sensitive nano-sensitizer with high disulfide density and high Pt(IV) prodrug loading capacity (up to 16.50% Pt and even higher), as described herein, is a promising way to overcome the cisplatin resistance and enhance the CRT efficacy. The optimized nanoparticles (NPs) (referred to as SSCV5) with moderate Pt loading (7.62% Pt) and median size (c.a. 40 nm) was screened out and used for further biological evaluation. Compared with free cisplatin, more drugs could be transported and released inside the cisplatin resistant cells (Hela-CDDP) by SSCV5 NPs. With the synergistic effect of GSH scavenging and mitochondrial damage, SSCV5 NPs can easily reverse the cisplatin resistance. Moreover, the higher nucleus DNA binding Pt content of SSCV5 NPs not only caused the DNA damage and apoptosis of Hela-CDDP cells but also sensitized these cells to X-Ray radiation. The in vivo safety and efficacy results showed that SSCV5 NPs effectively accumulated inside tumor and inhibited the growth of cisplatin resistant xenograft models while alleviating the serious side effect associated with cisplatin (the maximum tolerated cisplatin equivalent of single injection is higher than 20 mg/kg body weight). The intervention of exogenous radiation further improved the anticancer efficacy of SSCV5 NPs and caused the shrinkage of tumor volume, thus making this safe and facile nano-sensitizer a promising route for the neoadjuvant CRT of cervical cancers.

Towards rational design of RAD51-targeting prodrugs: platinum IV -artesunate conjugates with enhanced cytotoxicity against BRCA-proficient ovarian and breast cancer cells.

Nanoparticle Delivery of a Triple-Action Pt(iv) Prodrug to Overcome Cisplatin Resistance Via Synergistic Effect

Delivery of Platinum (II) Drugs with Bulky Ligands in Trans-Geometry for Overcoming Cisplatin Drug Resistance.

Interfering in Apoptosis and DNA Repair of Cancer Cells to Conquer Cisplatin Resistance by Platinum(iv) Prodrugs

Multitargeted Platinum(IV) Anticancer Complexes Bearing Pyridinyl Ligands as Axial Leaving Groups.

Design, Synthesis and Biological Evaluation of a Novel Platinum(ii) Complex Possessing Bioreductive Groups for Cancer Therapy

Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells

Synergistic Platinum(II) Prodrug Nanoparticles for Enhanced Breast Cancer Therapy.

Emerging JWA-targeted Pt(IV) Prodrugs Conjugated with CX-4945 to Overcome Chemo-Immune-resistance.

Synthesis and DNA Interactions Study of Novel Fluorinated Pyridinium Platinum (IV) Complexes with Tumor Targeting Activity

Engineering Novel Amphiphilic Platinum(IV) Complexes to Co-Deliver Cisplatin and Doxorubicin

Reduction-sensitive platinum (IV)-prodrug nano-sensitizer with an ultra-high drug loading for efficient chemo-radiotherapy of Pt-resistant cervical cancer in vivo

Human Serum Albumin Conjugated Nanoparticles for Ph and Redox-Responsive Delivery of a Prodrug of Cisplatin.

Platinum(IV) Complexes Conjugated with Phenstatin Analogue As Inhibitors of Microtubule Polymerization and Reverser of Multidrug Resistance.

A Trifunctional Pt(II) Complex Alleviates the NHEJ/HR-related DSBs Repairs to Evade Cisplatin-Resistance in NSCLC.

Rational Design of Platinum(ii) Complexes with Orthogonally Oriented Triazolyl Ligand with Emission Enhancement Characteristics for Cancer Chemotherapy in Vivo

Trastuzumab-Mediated Selective Delivery for Platinum Drug to Her2-Positive Breast Cancer Cells

Emerging platinum(IV) prodrug nanotherapeutics: A new epoch for platinum-based cancer therapy

A study on platinum(iv) species containing an estrogen receptor modulator to reverse tamoxifen resistance of breast cancer.

Dual-target platinum(IV) complexes exhibit antiproliferative activity through DNA damage and induce ER-stress-mediated apoptosis in A549 cells

Pt(IV) Prodrug Photoactivation: A Promising Strategy for Cancer Therapy